Immunic Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunic in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Immunic stock.
View analyst ratings for Immunic or view top-rated stocks.

Wall Street analysts have given Immunic a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Immunic wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Immunic saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 931,800 shares, a drop of 28.9% from the February 28th total of 1,310,000 shares. Based on an average trading volume of 265,200 shares, the short-interest ratio is presently 3.5 days.
View Immunic's Short Interest.

Immunic is scheduled to release its next quarterly earnings announcement on Friday, May 14th 2021.
View our earnings forecast for Immunic.

Immunic, Inc. (NASDAQ:IMUX) issued its quarterly earnings data on Friday, February, 26th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.13.
View Immunic's earnings history.

Immunic's stock was trading at $7.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IMUX shares have increased by 85.5% and is now trading at $14.38.
View which stocks have been most impacted by COVID-19.

9 Wall Street analysts have issued 12 month price targets for Immunic's stock. Their forecasts range from $45.00 to $71.00. On average, they anticipate Immunic's stock price to reach $58.38 in the next year. This suggests a possible upside of 305.9% from the stock's current price.
View analysts' price targets for Immunic or view top-rated stocks among Wall Street analysts.

Some companies that are related to Immunic include Stoke Therapeutics (STOK), Ocular Therapeutix (OCUL), Pliant Therapeutics (PLRX), Kiniksa Pharmaceuticals (KNSA), Phathom Pharmaceuticals (PHAT), Northwest Biotherapeutics (NWBO), Innoviva (INVA), Avid Bioservices (CDMO), Shattuck Labs (STTK), Protagonist Therapeutics (PTGX), Y-mAbs Therapeutics (YMAB), Dynavax Technologies (DVAX), Praxis Precision Medicines (PRAX), Repare Therapeutics (RPTX) and Omeros (OMER).
View all of IMUX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunic investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV), Moderna (MRNA), CymaBay Therapeutics (CBAY), NIO (NIO), NVIDIA (NVDA), TG Therapeutics (TGTX) and Ampio Pharmaceuticals (AMPE).

Immunic trades on the NASDAQ under the ticker symbol "IMUX."

Shares of IMUX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IMUX stock can currently be purchased for approximately $14.38.

Immunic has a market capitalization of $304.40 million. The company earns $-34,930,000.00 in net income (profit) each year or ($4.52) on an earnings per share basis.

Immunic employs 28 workers across the globe.

The official website for Immunic is www.immunic-therapeutics.com.

Immunic is headquartered at 1200 AVENUE SUITE 200, NEW YORK NY, 10036.

Immunic's mailing address is 1200 AVENUE SUITE 200, NEW YORK NY, 10036. The company can be reached via phone at 332-255-9818 or via email at [email protected]